Skip to main content
Swing Capital

Zim Laboratories Ltd

NSE: ZIMLAB BSE: 541400Pharma

Incorporated in 1989, Zim Laboratories Ltd manufactures formulation drugs and pre formulation ingredients in India and markets and sells these within and out side India[1]

₹96
52W: ₹59.3 — ₹127
PE 63.4 · Book ₹49.9 · +92% vs book
Market Cap₹514 Cr
Stock P/E63.4Price to Earnings
ROCE8.21%Return on Capital
ROE4.93%Return on Equity
Div. Yield0%Face Value ₹10

Weaknesses

  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Company has low interest coverage ratio.
  • −Promoter holding has decreased over last quarter: -2.91%
  • −The company has delivered a poor sales growth of 6.49% over past five years.
  • −Promoter holding is low: 30.4%
  • −Company has a low return on equity of 8.45% over last 3 years.

Shareholding Pattern

Promoters30.35%
FIIs0%
DIIs0.07%
Public69.57%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters33.26%33.26%33.26%33.26%33.26%33.26%33.26%30.35%▼2.9
FIIs0%0%0.21%▲0.20.01%▼0.20.03%▲0.00%▼0.00.02%▲0.00%▼0.0
DIIs0%0%0.24%▲0.20.24%0.24%0.24%0.2%▼0.00.07%▼0.1
Public66.74%66.73%▼0.066.29%▼0.466.49%▲0.266.46%▼0.066.52%▲0.166.52%69.57%▲3.0

Financial Statements

MetricSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales85.2695.82117.398289.7295.4108.5271.4388.39107.81
Expenses76.2984.64101.9674.1281.3283.6393.2867.182.2195.31
Operating Profit8.9711.1815.437.888.411.7715.244.336.1812.5
OPM %10.52%11.67%13.14%9.61%9.36%12.34%14.04%6.06%6.99%11.59%
Net Profit4.184.837.890.761.224.355.42-1.690.124.26
EPS ₹0.860.991.620.160.250.891.11-0.350.020.87

AI Insights

Revenue Trend

TTM revenue at ₹376Cr, up 0% YoY. OPM at 10%.

Debt Position

Borrowings at ₹121Cr. Debt-to-equity ratio: 0.62x. Moderate leverage.

Capex Cycle

CWIP at ₹46Cr (25% of fixed assets). Significant capex underway — growth runway building.

Institutional Flow

DIIs: 0.07% (+0.07pp change). FIIs: 0% (-0.06pp change). Promoters hold 30.35%.

Margin & Efficiency

ROCE improving from 0% (Mar 2015) to 8% (Mar 2025). Working capital days: 48.

Valuation

PE 63.4x with 8.21% ROCE. Price is 92% above book value of ₹49.9. Dividend yield: 0%.

Recent Announcements